Dianthus Therapeutics, Inc. research snapshot
DNTH AI stock analysis reads Dianthus Therapeutics as a clinical-stage biotechnology company developing next-generation therapies for severe autoimmune diseases, with a lead asset claseprubart (DNTH103) targeting active C1s complement and a second candidate DNTH212 targeting Type 1 IFN and B cell modulation. At the July 12, 2026 data cutoff, DNTH traded near $97.60 with a verified market capitalization near $5.34 billion. DNTH is pre-revenue with $1.11 billion cash, a recently initiated Phase 3 Emerge trial in generalized myasthenia gravis, and positive CIDP data that drove the stock near its 52-week high of $102.33. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$97.60
Market cap
$5.34 billion
AI score
51 / 100
Rating
Clinical-stage autoimmune biotech with promising pipeline, pre-revenue
Trend status
Near 52-week high on Phase 3 catalyst momentum and analyst consensus
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Dianthus is developing claseprubart, a potentially best-in-class anti-C1s antibody for complement-mediated autoimmune diseases, and DNTH212, a bifunctional fusion protein targeting Type 1 IFN and B cell pathways. Both assets address validated mechanisms with convenience advantages. | Medium |
| Moat | Moat potential comes from differentiated product design (extended half-life, high selectivity, subcutaneous self-administration), IP protection, and first-mover positioning in targeted complement and IFN-B cell modulation. Moat is unproven until clinical and commercial validation. | Low-medium |
| Management | Management has secured $1.11B in cash, initiated Phase 3 in gMG, generated positive CIDP data, and built a syndicate of reputable life science investors. Track record is early-stage with no approved products to date. | Medium |
| Financial trend | Pre-revenue with R&D and G&A expenses running at approximately $50M per quarter. Cash position of $1.11B provides runway into 2028+. No debt (0.11% debt/equity). | High |
| Valuation | At $97.60, DNTH trades at roughly 4.8x book value and carries a $4.22B enterprise value against $1.11B cash. Valuation is driven by pipeline probability-adjusted NPV rather than earnings, with analyst price targets ranging from $98 to $200. | Medium |
| Technical trend | Near the $102.33 52-week high after a strong run on CIDP data. Well above the $18.08 52-week low. Momentum is strong but the stock is extended from its recent breakout levels. | Medium |
| Risk level | High. Main risks include clinical trial failure or delay, regulatory setback, competitive development in gMG and CIDP, cash burn and future dilution, binary data-event volatility, and analyst downgrades on catalyst misses. | High |
| AI confidence | High for descriptive facts and financial position, medium for scenario valuations and technical levels, low for binary clinical outcome prediction. | Medium data confidence |
| Investment certainty | Low to medium certainty. This page frames scenarios and monitoring rules, not a buy or sell instruction. Clinical-stage biotech requires higher risk tolerance. | Low-medium |
DNTH AI stock forecast
The DNTH AI stock forecast uses scenario math around the $97.60 quote, the $1.11B cash position, and analyst consensus price targets. DNTH is a clinical-stage biotech where valuation depends primarily on Phase 3 data readouts and potential regulatory approvals rather than earnings growth.
$160 to $200
More likely if the Phase 3 Emerge trial in gMG delivers positive efficacy and safety data, CIDP development advances, DNTH212 shows encouraging proof-of-concept data, and the company remains an attractive acquisition target for larger pharma seeking autoimmune assets.
$100 to $140
More likely if Phase 3 enrollment proceeds on schedule, interim data reads are mixed but not negative, cash runway is maintained, and the stock trades in line with analyst consensus targets averaging around $127 to $135.
$40 to $70
More likely if Phase 3 data misses primary endpoints, regulatory feedback delays development, a competing therapy advances faster in gMG or CIDP, or the company needs dilutive financing before key catalysts.
DNTH AI technical analysis
DNTH AI technical analysis reflects a stock that has rallied sharply from its $18.08 52-week low to near $97.60, driven by positive clinical data and analyst upgrades. As of the July 12, 2026 data cutoff, the stock trades near its 52-week high of $102.33 with strong momentum but extended from its pre-data breakout levels.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $97.60 | Quote snapshots around the July 12, 2026 cutoff placed DNTH near $97.60, close to the 52-week high. |
| Near support | $85 to $90 | The $85 to $90 zone represents a potential pullback area after the recent rally, near prior resistance-turned-support levels. |
| Deeper support | $60 to $70 | Pre-CIDP data trading range. A break below this zone would suggest the catalyst-driven rally has fully reversed. |
| Near resistance | $100 to $103 | The 52-week high of $102.33 and the psychological $100 level represent immediate resistance. |
| Long-term resistance | $130 to $145 | The upper end of analyst price targets (Evercore $120, Wedbush $105, Jefferies $132, Oppenheimer $145) marks the next resistance zone if clinical momentum continues. |
| Momentum | Strong but extended | DNTH has rallied over 370% in the past year, indicating strong momentum but also elevated mean-reversion risk after binary catalysts. |
| Volume | Average volume near 1.37 million shares | Volume tends to spike on clinical data announcements and analyst updates, creating gap risk. |
| Volatility | High, typical of clinical-stage biotech | DNTH has a beta of 1.20 and can move 10-20%+ on single clinical data releases or regulatory news. |
| Invalidation | Close below $60 | A decisive close below the pre-CIDP data trading range would invalidate the current positive momentum setup. |
DNTH AI trading strategy
The DNTH AI trading strategy is a rules-based research framework for monitoring a clinical-stage autoimmune biotech approaching Phase 3 catalysts. It is not personal advice and should be paired with clinical trial updates, cash runway analysis, position sizing appropriate for binary risk, and a defined invalidation level.
Monitor Phase 3 Emerge trial enrollment progress, interim analysis timelines, and top-line data readouts. Position sizing should reflect the binary nature of clinical data events. Use analyst updates and trial disclosures as informational inputs.
Clinical-stage biotech can gap up or down 20-50% on data. Define maximum position size and portfolio allocation before catalysts. A failed Phase 3 readout is a thesis-ending event.
After positive data, watch for volume confirmation and follow-through above resistance levels. After negative data, the invalidation level around $60 becomes critical. DNTH212 proof-of-concept data and CIDP program updates are secondary catalysts.
Do not chase extended rallies post-catalyst without a pullback to a defined entry zone. Biotech stocks often give back part of post-data gains.
Track Phase 3 enrollment rates, clinical hold or safety signals, cash burn rate, dilution risk, partnership or M&A speculation, gMG and CIDP competitive landscape including argenx, UCB, and Sanofi programs, and analyst rating changes.
Reduce exposure if cash runway drops below 12 quarters, if a competitor reads positive data in the same indication, or if insider selling accelerates after the rally.
Investment research summary
Dianthus is engineering better antibodies for autoimmune patients. Customers (patients, physicians, payers) pay for convenient, effective, and safe treatments that improve on current standards like efgartigimod and IVIg.
The moat exists only on paper until clinical and commercial validation. Differentiated product design (half-life extension, C1s selectivity, subcutaneous delivery) and patent protection provide potential, but rivals like argenx, UCB, Sanofi, and others are already in the clinic for overlapping indications.
The thesis fails if claseprubart Phase 3 misses primary endpoints, if safety signals emerge, if a competitor achieves superior efficacy or convenience first, if commercial reimbursement is poor, or if the company needs dilutive financing before data.
Management should be judged by clinical execution, capital allocation between pipeline programs, partnership strategy, regulatory communication, and whether they preserve cash while advancing catalysts.
Autoimmune disease therapies represent a large and growing market with significant unmet need. The complement system and Type 1 IFN / B cell pathways are well-validated mechanisms. Dianthus sits at the intersection of targeted biologics and convenient subcutaneous administration.
At roughly $97.60 and a $4.22B enterprise value, DNTH prices in meaningful Phase 3 and commercial success probability. Margin of safety is limited for a pre-revenue biotech. A deep value entry would require a significant pullback on temporary negative sentiment.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DNTH price | $97.60 | Google Finance quote snapshot | July 12, 2026 |
| Market capitalization | $5.34 billion, verified as $97.60 x 54.67 million shares | financial_rigor.py market cap verification | July 12, 2026 |
| Cash position (mrq) | $1.11 billion | Yahoo Finance balance sheet | July 12, 2026 |
| Enterprise value | $4.22 billion | Yahoo Finance statistics | July 12, 2026 |
| Total debt/equity | 0.11% | Yahoo Finance balance sheet | July 12, 2026 |
| Net income (TTM) | -$173.66 million | Yahoo Finance income statement | July 12, 2026 |
| EPS (TTM) | -$4.23 | Yahoo Finance statistics | July 12, 2026 |
| Shares outstanding | 54.67 million | Google Finance summary | July 12, 2026 |
| 52-week range | $18.08 to $102.33 | Google Finance summary | July 12, 2026 |
| Analyst consensus | 11 analysts, all Strong Buy. Average target $127 to $135 | Google Finance analyst ratings | July 12, 2026 |
| Lead program | Claseprubart (DNTH103): anti-C1s antibody for gMG and CIDP. Phase 3 Emerge trial initiated June 2026 | Dianthus Therapeutics company website | July 12, 2026 |
| Second program | DNTH212: bifunctional fusion protein targeting pDC BDCA2 and BAFF/APRIL for autoimmune diseases | Dianthus Therapeutics company website | July 12, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell DNTH stock. Forecast scenarios are based on available public data, clinical trial disclosures, analyst estimates, and stated assumptions as of the data cutoff date and may be wrong. Clinical-stage biotechnology investments carry high risk, including the potential for complete loss of capital. Always verify current filings, clinical trial updates, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
